Join

Compare · LHDX vs TMDX

LHDX vs TMDX

Side-by-side comparison of Lucira Health Inc. (LHDX) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both LHDX and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
  • TMDX is the larger of the two at $3.83B, about 18.6x LHDX ($206.3M).
  • TMDX has hit the wire 4 times in the past 4 weeks while LHDX has been quiet.
  • TMDX has more recent analyst coverage (17 ratings vs 0 for LHDX).
MetricLHDXTMDX
Company
Lucira Health Inc.
TransMedics Group Inc.
Price
$0.45-19.60%
$110.72-2.24%
Market cap
$206.3M
$3.83B
1M return
-
+5.23%
1Y return
-
+22.79%
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Exchange
NASDAQ
NASDAQ
IPO
2021
2019
News (4w)
0
4
Recent ratings
0
17
LHDX

Lucira Health Inc.

Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California.

TMDX

TransMedics Group Inc.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.

Latest LHDX

Latest TMDX